EA202190358A1 - Способы генной терапии для контроля функции органов - Google Patents

Способы генной терапии для контроля функции органов

Info

Publication number
EA202190358A1
EA202190358A1 EA202190358A EA202190358A EA202190358A1 EA 202190358 A1 EA202190358 A1 EA 202190358A1 EA 202190358 A EA202190358 A EA 202190358A EA 202190358 A EA202190358 A EA 202190358A EA 202190358 A1 EA202190358 A1 EA 202190358A1
Authority
EA
Eurasian Patent Office
Prior art keywords
organ
function
control
organ function
gene therapy
Prior art date
Application number
EA202190358A
Other languages
English (en)
Russian (ru)
Inventor
Майкл Дж. Каплитт
Роберта Маронгиу
Original Assignee
Корнелл Юниверсити
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Корнелл Юниверсити filed Critical Корнелл Юниверсити
Publication of EA202190358A1 publication Critical patent/EA202190358A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1787—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EA202190358A 2018-07-31 2019-07-31 Способы генной терапии для контроля функции органов EA202190358A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862712669P 2018-07-31 2018-07-31
PCT/US2019/044290 WO2020028466A1 (en) 2018-07-31 2019-07-31 Gene therapy methods to control organ function

Publications (1)

Publication Number Publication Date
EA202190358A1 true EA202190358A1 (ru) 2021-05-04

Family

ID=69230802

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202190358A EA202190358A1 (ru) 2018-07-31 2019-07-31 Способы генной терапии для контроля функции органов

Country Status (14)

Country Link
US (1) US20210301306A1 (cg-RX-API-DMAC7.html)
EP (1) EP3829718A4 (cg-RX-API-DMAC7.html)
JP (2) JP2021533126A (cg-RX-API-DMAC7.html)
KR (1) KR20210052450A (cg-RX-API-DMAC7.html)
CN (1) CN113301956B (cg-RX-API-DMAC7.html)
AU (1) AU2019315445A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021001878A2 (cg-RX-API-DMAC7.html)
CA (1) CA3108324A1 (cg-RX-API-DMAC7.html)
EA (1) EA202190358A1 (cg-RX-API-DMAC7.html)
IL (1) IL280531A (cg-RX-API-DMAC7.html)
MX (1) MX2021001336A (cg-RX-API-DMAC7.html)
PH (1) PH12021550243A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202101042SA (cg-RX-API-DMAC7.html)
WO (1) WO2020028466A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013230776B2 (en) 2012-03-08 2015-12-03 Medtronic Af Luxembourg S.A.R.L. Immune system neuromodulation and associated systems and methods
AU2015358385B2 (en) 2014-12-03 2020-09-03 Medtronic Ireland Manufacturing Unlimited Company Systems and methods for modulating nerves or other tissue
US10524859B2 (en) 2016-06-07 2020-01-07 Metavention, Inc. Therapeutic tissue modulation devices and methods
CN115707773A (zh) * 2021-08-20 2023-02-21 中国科学院深圳先进技术研究院 一种利用交感神经控制血管内皮细胞异质性的方法
WO2023019565A1 (zh) * 2021-08-20 2023-02-23 中国科学院深圳先进技术研究院 一种利用交感神经控制血管内皮细胞异质性的方法
CN116019909B (zh) * 2022-09-16 2025-07-29 上海市第十人民医院 一种CRISPR/Cas9纳米系统
CN116115758B (zh) * 2022-11-22 2024-12-03 上海市内分泌代谢病研究所 Gabaa受体作为靶点在制备或筛选降血脂、治疗肥胖和/或改善代谢的药物中的应用
CN120699131B (zh) * 2024-12-04 2025-12-09 良渚实验室 治疗帕金森病的化学遗传学基因治疗新方案

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US4863457A (en) 1986-11-24 1989-09-05 Lee David A Drug delivery device
US5378475A (en) 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
US5814618A (en) 1993-06-14 1998-09-29 Basf Aktiengesellschaft Methods for regulating gene expression
US5464758A (en) 1993-06-14 1995-11-07 Gossen; Manfred Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
US5443505A (en) 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
US6342390B1 (en) 1994-11-23 2002-01-29 The United States Of America As Represented By The Secretary Of Health And Human Services Lipid vesicles containing adeno-associated virus rep protein for transgene integration and gene therapy
FR2814642B1 (fr) 2000-10-03 2005-07-01 Ass Pour Le Dev De La Rech En Souris transgenique pour la recombinaison ciblee mediee par la cre-er modifiee
US6723551B2 (en) 2001-11-09 2004-04-20 The United States Of America As Represented By The Department Of Health And Human Services Production of adeno-associated virus in insect cells
CA2566257A1 (en) 2004-05-07 2005-11-24 Applera Corporation Genetic polymorphisms associated with vascular diseases, methods of detection and uses thereof
DE23193606T1 (de) * 2005-04-07 2024-02-15 The Trustees Of The University Of Pennsylvania Verfahren zur erhöhung der funktion eines aav-vektors
DK2561073T3 (en) 2010-04-23 2016-12-12 Univ Massachusetts Aav vectors targeted to central nervous system and methods of use thereof
EP4124346A3 (en) * 2012-06-19 2023-04-19 University of Florida Research Foundation, Inc. Compositions and methods for treating diseases
GB201403684D0 (en) * 2014-03-03 2014-04-16 King S College London Vector
WO2016054557A1 (en) * 2014-10-03 2016-04-07 University Of Massachusetts Novel high efficiency library-identified aav vectors
AU2016324317A1 (en) * 2015-09-17 2018-03-08 Coda Biotherapeutics, Inc. Compositions and methods for treating neurological disorders
US20170218842A1 (en) * 2016-02-02 2017-08-03 General Electric Company Adjusting Airflow Distortion in Gas Turbine Engine
CA3011939A1 (en) * 2016-02-02 2017-08-10 University Of Massachusetts Method to enhance the efficiency of systemic aav gene delivery to the central nervous system
EP3426307B1 (en) * 2016-03-09 2023-09-06 Assaf, Fadi Using dreadd for neuronal modulation in treating neuronal diseases
MA44546B1 (fr) * 2016-06-15 2021-03-31 Univ California Virus adéno-associés variants et procédés d'utilisation
JPWO2018008770A1 (ja) * 2016-07-06 2019-04-18 厚範 神谷 末梢神経を操作する方法、脳および脊髄を除く臓器などにおいて神経細胞機能を変化させる機能を発生させる方法、および新規疾病の予防または治療方法、ならびに末梢神経投与用医薬
IL292382A (en) * 2019-10-22 2022-06-01 Applied Genetic Tech Corporation Adeno-associated virus (aav) systems for treatment of progranulin associated neurodegenerative diseases or disorders

Also Published As

Publication number Publication date
WO2020028466A1 (en) 2020-02-06
KR20210052450A (ko) 2021-05-10
US20210301306A1 (en) 2021-09-30
EP3829718A1 (en) 2021-06-09
MX2021001336A (es) 2021-09-10
CA3108324A1 (en) 2020-02-06
CN113301956A (zh) 2021-08-24
JP2021533126A (ja) 2021-12-02
IL280531A (en) 2021-03-25
EP3829718A4 (en) 2022-06-22
PH12021550243A1 (en) 2021-11-22
CN113301956B (zh) 2025-06-24
BR112021001878A2 (pt) 2021-04-27
SG11202101042SA (en) 2021-02-25
AU2019315445A1 (en) 2021-03-18
JP7890339B2 (ja) 2026-07-14
JP2024041871A (ja) 2024-03-27

Similar Documents

Publication Publication Date Title
PH12021550243A1 (en) Gene therapy methods to control organ function
Lingel et al. CTLA-4 (CD152): A versatile receptor for immune-based therapy
PH12019502870A1 (en) Small molecule modulators of human sting
MY209860A (en) Gene therapy vectors for treating heart disease
PH12021551409A1 (en) Kif18a inhibitors
MX2021007104A (es) Inhibidores de kif18a.
PH12019502345A1 (en) Methods of treatment using a jak inhibitor compoud
MX2024011808A (es) Metodos y sistemas para regular condicionalmente la expresion genica
EA201990747A1 (ru) Способы лечения иммунных нарушений с применением белков, связывающих pd–1
MX2023008760A (es) Terapia combinada de lasmiditan y un antagonista de cgrp para el uso en el tratamiento de la migra?a.
ZA201705628B (en) Methods and compositions for treating genetic eye diseases
MX2022000112A (es) Anticuerpos dirigidos contra gen 3 de activacion de linfocito (lag-3).
EA202092718A1 (ru) Композиции для контроля патогенов и пути их применения
MX2022002198A (es) Composiciones y métodos para modular el empalme y la expresión de proteínas.
BR112018009645A2 (pt) composições e métodos para a expressão de vários polipeptídeos biologicamente ativos a partir de um único vetor para tratamento de condições cardíacas e outras patologias
JP2016512781A5 (cg-RX-API-DMAC7.html)
JOP20210033B1 (ar) جرعة ليلية مزمنة من لاسميديتان للوقاية من الصداع النصفي
WO2021216738A3 (en) Compositions and methods of generating an immune response
MX2018015172A (es) Metodos para tratar cancer pancreatico.
EA202090700A1 (ru) Компетентные по репликации аденовирусные векторы
EA202092282A1 (ru) Способы лечения минимального остаточного рака
PH12018501695A1 (en) Substituted -oxyimidazolyl-carboxamides as pest control agents
EA202192757A1 (ru) Способ лечения опухолей
MX2020006976A (es) Anticuerpos del receptor de tipo i del polipeptido activador de la adenilato?ciclasa hipofisaria (pac1) y sus usos.
MX2023013697A (es) Vectores vegetales, composiciones y usos relacionados con los mismos.